STERIS plc (STE) is a global leader in infection prevention and sterilization products, serving healthcare, pharma, and research. Valued at $24.5 billion, they focus on patient safety and operational efficiency. Despite underperforming the market, their stock is up 20.9% in 2025, beating the S&P 500. Their FY 2026 Q1 earnings saw revenue rise 9% to $1.39 billion, with adjusted EPS up 15% to $2.34. Analysts expect EPS to grow 8.9% to $9.08 for the fiscal year, with a consensus rating of “Strong Buy” from nine analysts. Morgan Stanley upgraded Steris to “Overweight” with a price target of $276, signaling potential growth.

Read more at Yahoo Finance: What Are Wall Street Analysts’ Target Price for STERIS Stock?